A not-for-profit community journal that reviews the most important advances in the clinical management of HIV and access to treatment.
About HTB
Editor: Simon Collins. Contributing editor: Polly Clayden. ISSN 1472-4863.
Subscribe
Subscriptions are free — by post, email and online.
Medical review board
Each issue of HTB is circulated for comments to our medical review board.
Recent arcticles
- Volume 14 Number 3/4 March/April 2013 PDF 1 April 2013.
- Volume 14 Number 3/4 March/April 2013 1 April 2013.
- 20th Conference on Retroviruses and Opportunistic Infections (CROI) 3-6 March 2013, Atlanta 1 April 2013.
- ARV pipeline: dolutegravir, TAF (GS-7340), MK-1439 and cenicriviroc 1 April 2013.
- ARV pipeline: long-acting formulations of rilpivirine, GSK-744 and nanoformulations 1 April 2013.
- Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial 1 April 2013.
- Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children 1 April 2013.
- Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years 1 April 2013.
- Pharmacokinetics of currently available antiretroviral options for young children 1 April 2013.
- Safety of transplacental raltegravir in neonates and washout pharmacokinetics 1 April 2013.
- Tenofovir use in children 1 April 2013.
- ddI resistance in South African children failing an abacavir or d4T based first-line regimen 1 April 2013.
- Statin use in HIV positive people 1 April 2013.
- RIFAQUIN study demonstrates once-weekly dosing during follow-up phase of TB treatment 1 April 2013.
- Combining Xpert and LAM urine testing improves TB diagnostic sensitivity 1 April 2013.
- Deferring ART by four weeks reduces mortality in patients diagnosed with cryptococcal meningitis 1 April 2013.
- Monthly injection protects macaques from rectal exposure: results should fast-track human studies for advanced PrEP options 1 April 2013.
- Tenofovir DF ring protects macaques from vaginal exposure 1 April 2013.
- VOICE study reports low adherence as reason for lack of efficacy for PrEP: anal sex common in African heterosexuals 1 April 2013.
- Further studies on how male circumcision may reduce HIV transmission 1 April 2013.